Literature DB >> 22020607

Epidural administration of spinal nerves with the tumor necrosis factor-alpha inhibitor, etanercept, compared with dexamethasone for treatment of sciatica in patients with lumbar spinal stenosis: a prospective randomized study.

Seiji Ohtori1, Masayuki Miyagi, Yawara Eguchi, Gen Inoue, Sumihisa Orita, Nobuyasu Ochiai, Shunji Kishida, Kazuki Kuniyoshi, Junichi Nakamura, Yasuchika Aoki, Tetsuhiro Ishikawa, Gen Arai, Hiroto Kamoda, Miyako Suzuki, Masashi Takaso, Takeo Furuya, Tomoaki Toyone, Kazuhisa Takahashi.   

Abstract

STUDY
DESIGN: Prospective randomized trial.
OBJECTIVE: To examine the effect of the tumor necrosis factor alpha (TNF-α) inhibitor, etanercept, on radicular pain by its epidural administration onto spinal nerves in patients with lumbar spinal stenosis. SUMMARY OF BACKGROUND DATA: TNF-α is thought to play a crucial role in the radicular pain caused by lumbar disc herniation and spinal stenosis. Intravenous infusion of infliximab for sciatica has been examined in 2 studies; however, the results were equivocal.
METHODS: Eighty patients with low back and radicular leg pain were investigated. We diagnosed the patients by physical examination, and X-ray and magnetic resonance imaging. In 40 patients, we epidurally administered 2.0 mL of lidocaine and 10 mg of etanercept onto the affected spinal nerve, and 2.0 mL of lidocaine and 3.3 mg of dexamethasone was used in 40 patients. Low back pain, leg pain, and leg numbness were evaluated using a visual analogue scale (VAS) and Oswestry Disability Index (ODI) score before and for 1 month after epidural administration.
RESULTS: Low back pain, leg pain, and leg numbness in the 2 groups were not significantly different before epidural administration. Epidural administration of etanercept was more effective than dexamethasone for leg pain (3 days, and 1, 2, and 4 weeks: P < 0.05), low back pain (3 days, and 1 and 2 weeks: P < 0.05), and leg numbness (3 days, and 1 and 2 weeks: P < 0.05). No adverse event was observed in either group.
CONCLUSION: Our results indicate that epidural administration of a TNF-α inhibitor onto the spinal nerve produced pain relief, but no adverse event. TNF-α inhibitors may be useful tools for the treatment of radicular pain caused by spinal stenosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22020607     DOI: 10.1097/BRS.0b013e318238af83

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  38 in total

1.  Nanoparticle fullerol alleviates radiculopathy via NLRP3 inflammasome and neuropeptides.

Authors:  Li Jin; Mengmeng Ding; Azra Oklopcic; Bayan Aghdasi; Li Xiao; Ziyi Li; Vesna Jevtovic-Todorovic; Xudong Li
Journal:  Nanomedicine       Date:  2017-04-09       Impact factor: 5.307

Review 2.  Role of cytokines in intervertebral disc degeneration: pain and disc content.

Authors:  Makarand V Risbud; Irving M Shapiro
Journal:  Nat Rev Rheumatol       Date:  2013-10-29       Impact factor: 20.543

Review 3.  [Biotechnological therapies for the treatment of back pain: alternatives to corticosteroids].

Authors:  C Moser; H-J Thiel; D Grönemeyer
Journal:  Orthopade       Date:  2013-12       Impact factor: 1.087

Review 4.  Surgical and nonsurgical treatments for lumbar spinal stenosis.

Authors:  Gen Inoue; Masayuki Miyagi; Masashi Takaso
Journal:  Eur J Orthop Surg Traumatol       Date:  2016-07-25

5.  Lentiviral CRISPR Epigenome Editing of Inflammatory Receptors as a Gene Therapy Strategy for Disc Degeneration.

Authors:  Niloofar Farhang; Matt Ginley-Hidinger; Kristofer C Berrett; Jason Gertz; Brandon Lawrence; Robby D Bowles
Journal:  Hum Gene Ther       Date:  2019-07-17       Impact factor: 5.695

Review 6.  Targeting cytokines for treatment of neuropathic pain.

Authors:  Alice L Hung; Michael Lim; Tina L Doshi
Journal:  Scand J Pain       Date:  2017-08-24

7.  Anti-RANKL antibodies decrease CGRP expression in dorsal root ganglion neurons innervating injured lumbar intervertebral discs in rats.

Authors:  Masashi Sato; Kazuhide Inage; Yoshihiro Sakuma; Jun Sato; Sumihisa Orita; Kazuyo Yamauchi; Yawara Eguchi; Nobuyasu Ochiai; Kazuki Kuniyoshi; Yasuchika Aoki; Junichi Nakamura; Masayuki Miyagi; Miyako Suzuki; Gou Kubota; Takeshi Sainoh; Kazuki Fujimoto; Yasuhiro Shiga; Koki Abe; Hiroto Kanamoto; Gen Inoue; Kazuhisa Takahashi; Seiji Ohtori
Journal:  Eur Spine J       Date:  2015-06-14       Impact factor: 3.134

Review 8.  Disc in flames: Roles of TNF-α and IL-1β in intervertebral disc degeneration.

Authors:  Z I Johnson; Z R Schoepflin; H Choi; I M Shapiro; M V Risbud
Journal:  Eur Cell Mater       Date:  2015-09-21       Impact factor: 3.942

9.  Fibrin-genipin annulus fibrosus sealant as a delivery system for anti-TNFα drug.

Authors:  Morakot Likhitpanichkul; Yesul Kim; Olivia M Torre; Eugene See; Zepur Kazezian; Abhay Pandit; Andrew C Hecht; James C Iatridis
Journal:  Spine J       Date:  2015-04-23       Impact factor: 4.166

10.  Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept.

Authors:  Edward Tobinick; Nancy M Kim; Gary Reyzin; Helen Rodriguez-Romanacce; Venita DePuy
Journal:  CNS Drugs       Date:  2012-12       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.